IDEAL study: A real-world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX-FP) in patients with haemophilia B in Italy.
Annarita TagliaferriAngelo Claudio MolinariFlora PeyvandiAntonio CoppolaFrancesco DemartisChiara BiasoliAlessandra BorchielliniDorina CultreraRaimondo De CristofaroFilomena DanielePaola GiordanoEmanuela MarchesiniMaurizio MargaglioneRenato MarinoBerardino PollioPaolo RadossiCristina SantoroRita Carlotta SantoroSergio SiragusaGianluca SottilottaAlberto TosettoLydia PiscitelliMaria Rosaria VillaEzio ZanonAdele FinardiIrene SchiavettiDaniella VaccariGiancarlo CastamanPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2022)
Treatment with rIX-FP reduced infusion frequency, while providing higher FIX trough levels with substantial benefit in terms of annualised bleeding rate and a good safety profile.